 |
인쇄하기
취소
|
Oscotec files IND application to US FDA
Oscotec Inc. said it has filed an application of its osteoarthritis medicine OCT-1547 to the US Food and Drug Administration and EMCA in Europe, it was announced on March 19.
OCT-1547 inhibits the differentiation and activity of osteoclasts by blocking the signal transduction necessary for osteoclast differentiation.
OCT-1547 has a completely different action of mechanism from that of cur...
OCT-1547 inhibits the differentiation and activity of osteoclasts by blocking the signal transduction necessary for osteoclast differentiation.
OCT-1547 has a completely different action of mechanism from that of cur...
Fees
- Email service daily and homepage access.
- $300 per month.
- 5 Email holders per each company.
- Anual contract base.
Copyright Yakup.com All rights reserved.
약업닷컴의 모든 컨텐츠는 저작권법의 보호를 받습니다. 무단 전재⋅복사⋅배포 등을 금합니다.
약업닷컴의 모든 컨텐츠는 저작권법의 보호를 받습니다. 무단 전재⋅복사⋅배포 등을 금합니다.